Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

4.5%

7 terminated/withdrawn out of 156 trials

Success Rate

95.1%

+8.5% vs industry average

Late-Stage Pipeline

32%

50 trials in Phase 3/4

Results Transparency

55%

74 of 135 completed trials have results

Key Signals

6 recruiting74 with results7 terminated

Enrollment Performance

Analytics

Phase 1

64(42.4%)

Phase 3

45(29.8%)

Phase 2

35(23.2%)

Phase 4

5(3.3%)

N/A

2(1.3%)

151Total

Phase 1(64)

Phase 3(45)

Phase 2(35)

Phase 4(5)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (156)

Showing 20 of 156 trials

NCT05953480Phase 2Completed

A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

Role: lead

NCT00200356Phase 4Completed

Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke

Role: lead

NCT07214571Phase 2Recruiting

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

Role: lead

NCT05588323Phase 1Recruiting

Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids

Role: lead

NCT00415519Phase 3Completed

Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III

Role: lead

NCT00424463Phase 3Completed

Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Role: lead

NCT04165824Phase 3Completed

Safety Study of Oral Edaravone Administered in Subjects With ALS

Role: lead

NCT01492686Phase 3Completed

Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis

Role: lead

NCT00330681Phase 3Completed

Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Role: lead

NCT05568615Phase 3Completed

Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS

Role: lead

NCT04577404Phase 3Completed

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Role: lead

NCT04569084Phase 3Terminated

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

Role: lead

NCT04254913Phase 1Completed

Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy

Role: lead

NCT04481750Phase 1Completed

Study of Oral Edaravone in Healthy Adult Males

Role: lead

NCT03346538Phase 2Terminated

Dose Finding Study of MCI-186 in Acute Ischemic Stroke

Role: lead

NCT00821821Phase 2Completed

Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke

Role: lead

NCT05342597Phase 1Completed

Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)

Role: lead

NCT04481789Phase 1Completed

Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)

Role: lead

NCT03289234Phase 1Completed

Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment

Role: lead

NCT04029090Phase 1Completed

A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects

Role: lead